CYNO Cynosure - Class A (MM)

Company Gains New Market for Its Ground-Breaking Laser-Assisted Lipolysis Technology WESTFORD, Mass., June 12 /PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that it has received regulatory clearance to market and sell the Smartlipo LaserBodySculpting(SM) Workstation in Canada. "We are delighted about the opportunity to make the Smartlipo procedure available to Canadians," said Cynosure President and Chief Executive Officer Michael Davin. "With this approval, all five of our flagship products, including the Affirm(TM) Anti-Aging Workstation, the Cynergy(TM) Vascular Workstation, the TriActive(TM) Cellulite Workstation and the Elite(TM) Aesthetic Workstation are being marketed in Canada, enabling us to offer the Canadian medical community a comprehensive range of aesthetic and anti-aging solutions." Introduced by Cynosure in January, the minimally invasive Smartlipo Workstation is an innovative system designed as an alternative to traditional liposuction in patients with smaller areas of localized fat. The system's proprietary pulsing format delivers laser energy that liquefies localized deposits of fat that is then removed through a cannula. In addition, the laser energy coagulates the tissue, thereby sculpting body contours and tightening the skin. The procedure generally causes less bleeding, swelling and bruising than traditional liposuction, resulting in fewer complications and faster recovery. Cynosure received U.S. Food and Drug Administration clearance to market Smartlipo in the fourth quarter of 2006. Dr. Barry A.S. Lycka, an internationally known cosmetic dermatologist and surgeon who practices in Edmonton, Alberta, Canada, said, "Consumers today place a priority on looking healthier and more youthful. By enhancing a patient's appearance, the Smartlipo Workstation has the ability to improve overall quality of life, without the potentially serious complications and lengthy recovery times of traditional liposuction. Smartlipo's ability to target localized deposits of fat, and treat multiple areas in a single session, make this an exciting and promising technology." Cynosure's Smartlipo family of products is composed of a 6-watt workstation as well as a newly launched 10-watt workstation designed for higher volume aesthetic practices. The Company currently has a 10-person specialty surgical sales force dedicated to marketing Smartlipo workstations throughout North America. About Cynosure, Inc. Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com/ . Safe Harbor Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about expectations stemming from Health Canada clearance of the Smartlipo LaserBodySculpting(SM) Workstation, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements contain the words "believes," "anticipates," "plans," "expects," "will" and similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the success of the Smartlipo Workstation, changes in consumer preferences, competition in the aesthetic laser industry as well economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release. Contact: Scott Solomon Vice President Sharon Merrill Associates, Inc. 617.542.5300 DATASOURCE: Cynosure, Inc. CONTACT: Scott Solomon, Vice President of Sharon Merrill Associates, Inc., +1-617-542-5300, Web site: http://www.cynosurelaser.com/

Copyright